Bank of New York Mellon Corp Invests $1.97 Billion in Thermo Fisher Scientific Inc. $TMO

Key Points

• Bank of New York Mellon acquired 3.94 million Thermo Fisher Scientific shares worth approximately $1.97 billion, giving it a 1.07% stake. Institutional investors collectively own 89.23% of the company.
• Thermo Fisher reported quarterly EPS of $6.03, beating estimates of $5.71, while revenue rose 10.5% year over year to $11.99 billion. The company reaffirmed fiscal 2026 EPS guidance of $24.93–$25.33.
• Analysts maintain a favorable outlook, with a consensus “Moderate Buy” rating and an average price target of $619.41; however, company insiders have sold $37.7 million of stock over the past 90 days.

Bank of New York Mellon Corp bought a new stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 3,938,410 shares of the medical research company's stock, valued at approximately $1,974,561,000. Bank of New York Mellon Corp owned approximately 1.07% of Thermo Fisher Scientific as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of TMO. Brighton Jones LLC boosted its holdings in Thermo Fisher Scientific by 28.9% in the 4th quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company's stock valued at $2,293,000 after purchasing an additional 988 shares during the last quarter. Revolve Wealth Partners LLC raised its position in shares of Thermo Fisher Scientific by 4.2% during the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company's stock valued at $255,000 after buying an additional 20 shares during the period. Darwin Wealth Management LLC acquired a new position in Thermo Fisher Scientific in the second quarter valued at approximately $170,000. Raymond James Financial Inc. grew its position in Thermo Fisher Scientific by 7.4% in the second quarter. Raymond James Financial Inc. now owns 778,822 shares of the medical research company's stock worth $315,781,000 after acquiring an additional 53,542 shares during the period. Finally, California State Teachers Retirement System increased its stake in Thermo Fisher Scientific by 0.4% during the second quarter. California State Teachers Retirement System now owns 602,031 shares of the medical research company's stock worth $244,099,000 after acquiring an additional 2,262 shares during the last quarter. Hedge funds and other institutional investors own 89.23% of the company's stock.

Insider Buying and Selling

In related news, COO Gianluca Pettiti sold 400 shares of the firm's stock in a transaction that occurred on Monday, July 27th. The shares were sold at an average price of $565.00, for a total value of $226,000.00. Following the sale, the chief operating officer owned 24,651 shares of the company's stock, valued at $13,927,815. This trade represents a 1.60% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael D. Shafer sold 25,500 shares of the business's stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $600.00, for a total transaction of $15,300,000.00. Following the transaction, the executive vice president owned 20,994 shares of the company's stock, valued at approximately $12,596,400. The trade was a 54.85% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 63,493 shares of company stock worth $37,657,681 over the last ninety days. Company insiders own 0.33% of the company's stock.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on the company. Morgan Stanley increased their price target on Thermo Fisher Scientific from $620.00 to $650.00 and gave the stock an "overweight" rating in a report on Friday, July 24th. Jefferies Financial Group reaffirmed a "buy" rating and issued a $630.00 target price on shares of Thermo Fisher Scientific in a research report on Thursday, July 23rd. Wells Fargo & Company lowered their target price on shares of Thermo Fisher Scientific from $675.00 to $615.00 and set an "overweight" rating for the company in a research note on Friday, May 8th. Robert W. Baird reduced their price target on shares of Thermo Fisher Scientific from $653.00 to $639.00 and set an "outperform" rating on the stock in a research note on Friday, April 24th. Finally, Barclays upped their price objective on shares of Thermo Fisher Scientific from $625.00 to $650.00 and gave the stock an "overweight" rating in a report on Friday, July 24th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have given a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $619.41.

Thermo Fisher Scientific Stock Performance

NYSE TMO opened at $628.24 on Friday. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.55 and a quick ratio of 1.18. The company has a market cap of $232.29 billion, a P/E ratio of 33.79, a P/E/G ratio of 2.50 and a beta of 0.85. The stock has a 50-day moving average of $539.33 and a two-hundred day moving average of $508.86. Thermo Fisher Scientific Inc. has a 1-year low of $435.27 and a 1-year high of $643.99.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.71 by $0.32. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The business had revenue of $11.99 billion for the quarter, compared to analysts' expectations of $11.71 billion. During the same quarter in the prior year, the company earned $4.28 earnings per share. The business's quarterly revenue was up 10.5% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. As a group, analysts anticipate that Thermo Fisher Scientific Inc. will post 25.12 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Tuesday, September 15th will be issued a dividend of $0.47 per share. The ex-dividend date is Tuesday, September 15th. This represents a $1.88 annualized dividend and a yield of 0.3%. Thermo Fisher Scientific's dividend payout ratio is 10.11%.

About Thermo Fisher Scientific

Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source